Nuvation Bio Inc（NUVB）の財務NUVBNuvation Bio Inc

Evaluating the bottom line, Nuvation Bio Inc. maintains a gross margin of 70.11%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -161.06%, while the net margin is -198.31%. These profitability ratios, combined with a Return on Equity (ROE) of -47.81%, provide a clear picture of how effectively NUVB converts its operational activities into shareholder value.

In the context of the broader market, NUVB competes directly with industry leaders such as COAG and STOK. With a market capitalization of $1.67B, it holds a significant position in the sector. When comparing efficiency, NUVB's gross margin of 70.11% stands against COAG's N/A and STOK's 100.00%. Such benchmarking helps identify whether Nuvation Bio Inc. is trading at a premium or discount relative to its financial performance.

Nuvation Bio has demonstrated a significant increase in total revenue, with Q1 2026 revenue reaching $83.23 million, up from $13.12 million in Q3 2025. The gross margin has also improved dramatically, reaching 92.80% in Q1 2026, indicating strong operational efficiency.